DrugPatentWatch Database Preview
Abraxis Bioscience Company Profile
What is the competitive landscape for ABRAXIS BIOSCIENCE, and when can generic versions of ABRAXIS BIOSCIENCE drugs launch?
ABRAXIS BIOSCIENCE has one approved drug.
There are twelve US patents protecting ABRAXIS BIOSCIENCE drugs.
There are two hundred and sixty-six patent family members on ABRAXIS BIOSCIENCE drugs in thirty-one countries and thirteen supplementary protection certificates in ten countries.
Summary for Abraxis Bioscience
| International Patents: | 266 |
| US Patents: | 12 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
| Patent Litigation for Abraxis Bioscience: | See patent lawsuits for Abraxis Bioscience |
Drugs and US Patents for Abraxis Bioscience
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abraxis Bioscience | ABRAXANE | paclitaxel | FOR SUSPENSION;IV (INFUSION) | 021660-001 | Jan 7, 2005 | RX | Yes | Yes | 9,393,318 | ➤ Sign Up | ➤ Sign Up | ||||
| Abraxis Bioscience | ABRAXANE | paclitaxel | FOR SUSPENSION;IV (INFUSION) | 021660-001 | Jan 7, 2005 | RX | Yes | Yes | 8,314,156 | ➤ Sign Up | ➤ Sign Up | ||||
| Abraxis Bioscience | ABRAXANE | paclitaxel | FOR SUSPENSION;IV (INFUSION) | 021660-001 | Jan 7, 2005 | RX | Yes | Yes | 8,138,229 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Abraxis Bioscience | ABRAXANE | paclitaxel | FOR SUSPENSION;IV (INFUSION) | 021660-001 | Jan 7, 2005 | RX | Yes | Yes | 9,101,543 | ➤ Sign Up | ➤ Sign Up | ||||
| Abraxis Bioscience | ABRAXANE | paclitaxel | FOR SUSPENSION;IV (INFUSION) | 021660-001 | Jan 7, 2005 | RX | Yes | Yes | 9,511,046 | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Abraxis Bioscience
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abraxis Bioscience | ABRAXANE | paclitaxel | FOR SUSPENSION;IV (INFUSION) | 021660-001 | Jan 7, 2005 | 6,749,868 | ➤ Sign Up |
| Abraxis Bioscience | ABRAXANE | paclitaxel | FOR SUSPENSION;IV (INFUSION) | 021660-001 | Jan 7, 2005 | 5,439,686 | ➤ Sign Up |
| Abraxis Bioscience | ABRAXANE | paclitaxel | FOR SUSPENSION;IV (INFUSION) | 021660-001 | Jan 7, 2005 | 6,753,006 | ➤ Sign Up |
| Abraxis Bioscience | ABRAXANE | paclitaxel | FOR SUSPENSION;IV (INFUSION) | 021660-001 | Jan 7, 2005 | 6,096,331 | ➤ Sign Up |
| Abraxis Bioscience | ABRAXANE | paclitaxel | FOR SUSPENSION;IV (INFUSION) | 021660-001 | Jan 7, 2005 | RE41884 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for ABRAXIS BIOSCIENCE drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | For Injection Suspension | 100 mg/vial | ➤ Subscribe | 2015-12-11 |
Non-Orange Book US Patents for Abraxis Bioscience
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 9,855,220 | Methods of treating pancreatic cancer | ➤ Sign Up |
| 5,439,686 | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor | ➤ Sign Up |
| 9,012,518 | Compositions and methods of delivery of pharmacological agents | ➤ Sign Up |
| 5,635,207 | Methods for the preparation of blood substitutes for in vivo delivery | ➤ Sign Up |
| 5,650,156 | Methods for in vivo delivery of nutriceuticals and compositions useful therefor | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Abraxis Bioscience Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| China | 103405405 | ➤ Sign Up |
| Japan | 2016014073 | ➤ Sign Up |
| Japan | 2009185042 | ➤ Sign Up |
| Costa Rica | 20120528 | ➤ Sign Up |
| Hong Kong | 1119071 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Abraxis Bioscience Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 613 | Luxembourg | ➤ Sign Up | 91613, EXPIRES: 20220924 |
| 2014 00034 | Denmark | ➤ Sign Up | PRODUCT NAME: PACLITAXEL FORMULERET SOM ALBUMINBUNDNE NANOPARTIKLER; REG. NO/DATE: C(2013)9835 20131220 |
| 0961612/01 | Switzerland | ➤ Sign Up | PRODUCT NAME: PACLITAXELUM-ALBUMINUM; REGISTRATION NO/DATE: SWISSMEDIC 63182 26.08.2014 |
| 2014022 | Lithuania | ➤ Sign Up | PRODUCT NAME: PACLITAXELUM; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220 |
| 1 | Finland | ➤ Sign Up | |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.
